A condition affecting millions of women worldwide has been officially renamed, following more than a decade of international consultation.
Polycystic ovary syndrome, long known as PCOS, will now be called polyendocrine metabolic ovarian syndrome, or PMOS. The change aims to better reflect how the condition affects the whole body, not just the ovaries.
Experts involved in the decision say the new name could improve understanding, reduce stigma, and support earlier diagnosis and more coordinated care. The name change was announced at the European Congress of Endocrinology in Prague and was published in The Lancet.
What is PCOS and why the name mattered
PCOS is one of the most common hormonal disorders in women of reproductive age, affecting an estimated one in eight globally. It is linked to irregular periods, high levels of androgens such as testosterone, difficulties with ovulation, and a higher risk of metabolic problems including insulin resistance, type 2 diabetes and heart disease.
Despite its name, not everyone with PCOS has cysts on their ovaries. In fact, ovarian cysts are neither required for diagnosis nor present in all cases. This mismatch between the name and the biology has long caused confusion for patients and clinicians alike.
The old name has been criticised by medical and scientific community as misleading and incomplete. It is argued that it contributed to delayed diagnosis and an overly narrow focus on reproductive symptoms, while metabolic and hormonal aspects were sometimes overlooked.
What prompted the change
The renaming follows 14 years of discussion involving 56 academic, clinical and patient organisations worldwide. Rather than keeping the familiar PCOS acronym or choosing a vague alternative, the group agreed that a new name should describe the condition more accurately.
The agreed term, polyendocrine metabolic ovarian syndrome, highlights three core features:
- Polyendocrine, reflecting disruption across multiple hormone systems.
- Metabolic, recognising links to insulin resistance and cardiovascular risk.
- Ovarian, acknowledging the role of the ovaries without overstating cysts.
How PMOS better reflects what is known
Research over several decades has shown that PCOS involves complex interactions between hormones, metabolism and inflammation. Insulin resistance can worsen androgen excess, which in turn disrupts ovulation and menstrual cycles. These processes affect multiple organs and systems.
By removing the emphasis on “polycystic” ovaries, the new name avoids suggesting that ovarian cysts are central to the condition. This matters because some women with clear symptoms and hormonal changes have normal‑appearing ovaries on ultrasound, yet still experience significant health effects.
In plain terms, PMOS is intended to describe what clinicians already know, that this is a multisystem endocrine disorder (hormonal) with long‑term metabolic consequences.
How strong is the evidence behind the change?
The renaming itself is not based on a single new study, but on a large body of established clinical and biological evidence. The metabolic and hormonal features of the condition are well documented in human studies across different populations.
However, changing the name does not alter diagnostic criteria overnight, nor does it resolve ongoing debates about how best to classify and treat the condition.
The name change reflects current understanding, but research into causes, subtypes and optimal management is still evolving.
What this means for patients
For people already diagnosed with PCOS, the name change does not immediately alter medical care or treatment recommendations. Existing guidelines for diagnosis and management remain in place for now.
In the longer term, advocates hope the new name will:
- Reduce confusion around diagnosis.
- Encourage clinicians to assess metabolic and cardiovascular risk earlier.
- Help patients feel their symptoms are taken seriously beyond fertility concerns.
However, adjusting to a new term will take time, as all medical literature will have to be updated and the old name is better known than the new one.
Treatment and policy implications
Current treatments for PCOS focus on symptom management, including hormonal therapies, lifestyle measures to improve insulin sensitivity, and targeted treatment for fertility concerns where relevant. The name change does not introduce new therapies.
That said, experts in the study and committee believe PMOS may influence how research funding, clinical pathways and public health messaging develop.
A stronger emphasis on metabolic health could support earlier interventions to reduce long‑term risks such as diabetes and heart disease.
It is not yet clear how quickly the new terminology will be adopted in clinical practice, medical education and research literature. There are also unanswered questions about whether PMOS should eventually be divided into subtypes, reflecting differences in symptoms and risk profiles.
Further research is ongoing to better understand causes, early markers and personalised treatment approaches.
A shift in perspective, not a cure
The renaming of PCOS to PMOS does not change the lived experience of those affected, nor does it offer new treatments. Its significance lies in reframing a common condition in a way that better matches scientific evidence.
By recognising PMOS as a complex hormonal and metabolic disorder, rather than a problem defined by ovarian cysts, experts hope to improve understanding, care and research for a condition that has too often been misunderstood.
The post PMOS Replacing PCOS: A Deeper Dive into Why the Name Change Matters first appeared on PP Health Malaysia.
